探索XA因子抑制剂对血友病患者血栓生成的影响
Caroline Dix1, James D McFadyen2, Huyen A Tran3
1Department of Clinical Haematology, The Alfred Hospital, Melbourne, Victoria, Australia.
Thrombosis research
|April 11, 2024
概括
血友病患者 (PWH) 的心血管疾病管理正在发展. 在PWH中使用抗凝剂需要进一步研究,因为XA因子抑制剂会影响血栓生成,特别是在Emicizumab治疗中.
科学领域:
- 血液学 血液学 血液学
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 血友病 (PWH) 患者的心血管疾病 (CVD) 管理由于预期寿命的提高而变得越来越重要.
- 像非因子替代疗法 (NFRT) 这样的不断发展的治疗方法可能会减少PWH在历史上对心血管疾病的保护作用.
- 关于PWH抗凝剂安全性的证据有限.
研究的目的:
- 评估PWH中不同严重程度和治疗的血栓生成 (TG).
- 为了比较PWH中的TG与服用Xa因子 (FXa) 抑制剂的非血友病患者.
- 评估从PWH添加FXa抑制剂到血对艾米齐祖马布预防的影响.
主要方法:
- 这项研究包括40名患者.
- 用5pM组织因子 (TF) 启动血生成 (TG),使用校准的自动血镜.
- 在不同严重程度和治疗的PWH,健康对照和接受FXa抑制剂 (阿皮克萨班或里瓦罗克萨班) 的患者中评估了TG参数.
主要成果:
- 与轻度血友病患者相比,服用FXa抑制剂的患者表现出更高的内源性血栓潜力 (ETP) 和速度指数.
- 在艾米齐祖马布治疗中患有严重血友病的PWH改善了TG参数 (更高的ETP和峰值高度) 与未服用艾米齐祖马布的人相比.
- 将FXa抑制剂添加到PWH中的血中,使TG参数恢复到严重血友病中所见的水平.
结论:
- 血生成 (TG) 可能为血友病 (PWH) 患者的抗凝剂使用提供有价值的见解.
- FXa 抑制剂,艾米齐祖马布和TG之间的相互作用需要进一步研究,以确保PWH中安全的心血管疾病管理.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
689
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
689
Extrinsic and Intrinsic Pathways of Hemostasis
7.4K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.4K
Disorders of Hemostasis
881
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
881
Clot Retraction and Fibrinolysis
5.7K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.7K
Coagulation
6.4K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.4K
Introduction to Hemostasis
7.5K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
7.5K


